参麦注射液防治晚期非小细胞肺癌化疗不良反应的临床观察

Clinical Observation on Shenmai Injection in Preventing and Treating Adverse Reaction of Chemotherapy on Advanced Non-small Cell Lung Cancer

目的观察参麦注射液防治晚期非小细胞肺癌患者化疗引起不良反应的作用。方法将45例Ⅲb～Ⅳ期非小细胞肺癌患者随机分为治疗组(参麦注射液加化疗)和对照组(单纯化疗),均治疗3个周期,进行相关比较。结果治疗组和对照组的近期疗效在统计学上无明显差异(P>0．05),在Karnofsky评分、体重方面,两组比较差异均有显著性(P<0．05)。不良反应方面,治疗组在白细胞、血红蛋白减少方面程度低于对照组(P<0．05);而血小板减少、恶心呕吐、肝肾功能损害发生率,虽然治疗组均低于对照组,但两组比较,差异无显著性(P>0．05)。结论参麦注射液不影响晚期非小细胞肺癌患者化疗疗效,且能够提高生存质量、增加体重、减轻化疗的不良反应,一定程度上提高机体对化疗的耐受性。

Objective To observe the efficacy of Shenmai Injection （SI） in preventing and treating adverse reation of chemotherapy on advanced non-small cell lung cancer （NSCLC）. Methods Forty-five patients with NSCLC in Ⅲ b-Ⅳ stage were randomly divided into two groups, the control group treated with chemotherapy alone and the treated group with chemotherapy and SI. The therapeutic efficacy were evaluated after 3 treatment cycles. Results There was no significant difference in short-term effect between the two groups （ P 〉 0.05）, while it showed remarkable difference in Karnofsky scoring and body weight （P 〈 0.05）. The treated group showed a better effect than the control group in reducing adverse reaction, such as decrease of leucocyte and hemoglobin （P 〈 0.05）, while in the aspects of improving thrombocytopenia and the reducing occurrence of nausea/vomitting and alleviating injury of liver and kidney function, it only showed the lower value in the treat- ed group, but with no significant difference as compared with the control group （P 〉 0.05）. Conclusion SI could not raise the efficacy of chemotherapy on NSCLC, but improve the quality of life, raise the body weight of patients and alleviate adverse reaction of chemotherapy as myelosuppression so as to improve the tolerance of organism to chemotherapy.